Form 4: Rapport Therapeutics CSO Sells Shares, Exercises Options

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock and exercised options for 6,000 shares under a pre-arranged trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), engaged in multiple transactions involving the company's common stock.
• On February 17, 2026, Bredt sold a total of 8,500 shares of common stock across three separate transactions.
• The sales occurred at weighted average prices of $28.0211 (900 shares), $28.9497 (5,400 shares), and $29.5944 (2,200 shares).
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these sales, Bredt's direct beneficial ownership of common stock was 387,075 shares.
• On February 19, 2026, Bredt exercised options to acquire 6,000 shares of common stock at an exercise price of $1.8 per share.
• No shares were sold as part of this option exercise transaction.
• After the option exercise, Bredt's direct beneficial ownership of common stock increased to 393,075 shares.
• Bredt also beneficially owns 88,080 stock options (right to buy) after these transactions.
• The options exercised had a vesting schedule where 25% vested on August 7, 2024, with the remainder vesting in 36 equal monthly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider activities, involving both sales and option exercises under a pre-arranged plan, which typically do not signal significant changes in company fundamentals.

Positives

• The exercise of 6,000 stock options at a low price of $1.8 indicates a potential belief in the company's long-term value by the CSO.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a systematic approach to managing personal holdings rather than an immediate reaction to new information.

Negatives

• The sale of 8,500 shares of common stock by a Chief Scientific Officer could be perceived negatively by some investors, although it was part of a pre-arranged plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. While sales by executives can sometimes raise questions, the pre-arranged nature of these transactions often mitigates concerns about opportunistic selling based on non-public information. The exercise of options at a low strike price is a standard practice for executives to realize value from their compensation packages.

Stakeholder Impact

• Shareholders may observe a slight increase in the public float due to the sales, but the overall impact on the company's strategic direction or operational performance is negligible as these are personal financial management activities of an executive.

Key Dates

Recommendation

The filing details routine insider transactions (sales under a 10b5-1 plan and option exercises) by a Chief Scientific Officer. These types of transactions are generally not indicative of fundamental changes in the company's prospects and therefore do not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and industry trends.

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Insider Trading, Stock Sales, Option Exercise, David Bredt, Chief Scientific Officer, Rule 10b5-1 Plan